{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:26Z","timestamp":1788736106082,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103200","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:55:15Z","timestamp":1785772515000},"page":"103200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception"],"prefix":"10.1016","volume":"149","author":[{"given":"Myl\u00e8ne","family":"Wespiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Rochefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Gauduchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Perol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Heudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2026.103200_bb0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103200_bb0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","article-title":"Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors","volume":"10","author":"Travis","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103200_bb0015","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2020.23130","article-title":"Association of First Primary Cancer with Risk of subsequent primary Cancer among survivors of adult-onset cancers in the United States","volume":"324","author":"Sung","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","article-title":"Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study","volume":"25","author":"Kjaer","year":"2024","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103200_bb0025","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103200_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"Berrington de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12967-025-06151-9","article-title":"Decoding the mechanisms behind second primary cancers","volume":"23","author":"Zeng","year":"2025","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-025-08270-6","article-title":"Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications","volume":"313","author":"Kr\u00fcckel","year":"2026","journal-title":"Arch Gynecol Obstet"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103200_bb0045","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019\u2019 Group","year":"2008","journal-title":"Lancet Oncol"},{"issue":"10001","key":"10.1016\/j.ctrv.2026.103200_bb0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103200_bb0060","first-page":"107","article-title":"Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies","volume":"36","author":"Ghosh","year":"2025","journal-title":"Cancer Causes Control"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103200_bb0065","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103200_bb0070","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103200_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1039320","article-title":"Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0080","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.21037\/tcr-20-2166","article-title":"Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"4_Supplement","key":"10.1016\/j.ctrv.2026.103200_bb0085","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-GS1-10","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA breast cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103200_bb0095","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41416-022-01882-8","article-title":"Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies","volume":"127","author":"Zaman","year":"2022","journal-title":"Br J Cancer"},{"issue":"9754","key":"10.1016\/j.ctrv.2026.103200_bb0100","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0105","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/bjs\/znad231","article-title":"Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses","volume":"110","author":"Shah","year":"2023","journal-title":"Br J Surg"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103200_bb0110","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMoa067208","article-title":"Aspirin and the risk of colorectal cancer in relation to the expression of COX-2","volume":"356","author":"Chan","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/gutjnl-2020-320946","article-title":"Naproxen chemoprevention promotes immune activation in lynch syndrome colorectal mucosa","volume":"70","author":"Reyes-Uribe","year":"2021","journal-title":"Gut"},{"issue":"10240","key":"10.1016\/j.ctrv.2026.103200_bb0120","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2468-1253(24)00387-X","article-title":"Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Chia","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","article-title":"Low-dose aspirin for PI3K-altered localized colorectal cancer","volume":"393","author":"Martling","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103200_bb0135","unstructured":"NCCN [Internet]. 2026. Guidelines Detail. Disponible sur: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428."},{"key":"10.1016\/j.ctrv.2026.103200_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251344481","article-title":"Review of network Meta-analyses on the efficacy of Chemopreventive agents on colorectal adenomas and Cancer","volume":"32","author":"Ruan","year":"2025","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctrv.2026.103200_bb0145","article-title":"Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population","volume":"2","author":"Cai","year":"2026","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0150","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473708","article-title":"Emerging strategies for drug-based cancer risk reduction","volume":"45","author":"Daca-\u00c1lvarez","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2026.103200_bb0155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2147\/CLEP.S174120","article-title":"Efficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: systematic review and network meta-analysis","volume":"10","author":"Veettil","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103200_bb0160","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103200_bb0165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.breast.2014.10.005","article-title":"Cumulative risk of second primary contralateral breast cancer in BRCA1\/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis","volume":"23","author":"Molina-Montes","year":"2014","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0170","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0175","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.annonc.2021.04.023","article-title":"PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials","volume":"32","author":"Morice","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103200_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2021.08.016","article-title":"Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy","volume":"157","author":"Matsuo","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103200_bb0190","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.seminoncol.2015.09.009","article-title":"Repurposing old drugs to chemoprevention: the case of metformin","volume":"43","author":"Heckman-Stoddard","year":"2016","journal-title":"Semin Oncol"},{"issue":"7503","key":"10.1016\/j.ctrv.2026.103200_bb0200","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0205","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.2027","article-title":"Metformin use and development of esophageal squamous cell carcinoma","volume":"9","author":"Xie","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103200_bb0215","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103200_bb0220","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103200_bb0225","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13063-024-07929-w","article-title":"Cancer precision-prevention trial of metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol","volume":"25","author":"Dixon-Zegeye","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2026.103200_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2_suppl","key":"10.1016\/j.ctrv.2026.103200_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2026.44.2_suppl.18","article-title":"GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: evidence from a real-world head-to-head comparison","volume":"44","author":"Jones","year":"2026","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0245","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ctrv.2026.103200_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2026.103200_bb0255","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"50","key":"10.1016\/j.ctrv.2026.103200_bb0260","doi-asserted-by":"crossref","first-page":"29304","DOI":"10.18632\/oncotarget.25448","article-title":"Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics","volume":"9","author":"Ishikawa","year":"2018","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103200_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178429","article-title":"Molecular and immunomodulatory mechanisms of statins in inflammation and cancer therapeutics with emphasis on the NF-\u03baB, NLRP3 inflammasome, and cytokine regulatory axes","volume":"26","author":"Khan","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103200_bb0270","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103200_bb0275","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2013.54.4569","article-title":"Statin use after colorectal cancer diagnosis and survival: a population-based cohort study","volume":"32","author":"Cardwell","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0280","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ehjcvp\/pvad057","article-title":"Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis","volume":"9","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ctrv.2026.103200_bb0285","first-page":"439","article-title":"Statins prevent biochemical recurrence of prostate cancer after radical prostatectomy: a single-center retrospective study with a median follow-up of 51.20 months","volume":"12","author":"Jarimba","year":"2020","journal-title":"Res Rep Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103200_bb0290","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12282-022-01411-8","article-title":"Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors","volume":"30","author":"Bailey","year":"2023","journal-title":"Breast Cancer (Auckl)"},{"issue":"10170","key":"10.1016\/j.ctrv.2026.103200_bb0295","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209486","article-title":"Statin therapy in the treatment of active cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Farooqi","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0305","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/157591","article-title":"Role of nicotinamide in DNA damage, mutagenesis, and DNA repair","volume":"2010","author":"Surjana","year":"2010","journal-title":"J Nucleic Acids"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103200_bb0310","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103200_bb0315","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for skin-cancer chemoprevention in transplant recipients","volume":"388","author":"Allen","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/nu16010100","article-title":"The role of nicotinamide as chemo-preventive agent in NMSCs: a systematic review and meta-analysis","volume":"16","author":"Tosti","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0330","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0335","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.annonc.2020.09.001","article-title":"Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer","volume":"31","author":"Heudel","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0340","doi-asserted-by":"crossref","first-page":"e64900","DOI":"10.2196\/64900","article-title":"Impact of immune checkpoint inhibitors on second primary Cancer risk in patients with metastatic lung Cancer using real-world data from the TriNetX network: retrospective cohort study","volume":"21","author":"Heudel","year":"2025","journal-title":"JMIR Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0345","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1158\/1078-0432.CCR-25-3886","article-title":"The impact of immunotherapy on incidence of second primary malignancies: a surrogate for antitumor surveillance activation","volume":"32","author":"Adcock","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103200_bb0350","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.57807","article-title":"Development of secondary cancers in pre- vs post-ICI eligibility periods for metastatic cancers","volume":"9","author":"Li","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant Pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103200_bb0360","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","author":"Bourhis","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103200_bb0365","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.59603","article-title":"Adjuvant Pembrolizumab for stage IIB or IIC melanoma: a secondary analysis of a randomized clinical trial","volume":"9","author":"Leachman","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103200_bb0370","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10316","key":"10.1016\/j.ctrv.2026.103200_bb0375","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103200_bb0380","series-title":"Disponible sur","author":"2025 Cervical Cancer Elimination Progress Report | C4 [Internet]","year":"2026"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103200_bb0385","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ijc.70196","article-title":"The cervical cancer screening program in the north of Portugal: outcomes after nearly two decades of coexistence with the human papillomavirus vaccine","volume":"158","author":"S\u00e1","year":"2026","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0390","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0395","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103200_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004416","article-title":"Vaccines for immunoprevention of DNA mismatch repair deficient cancers","volume":"10","author":"Hernandez-Sanchez","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103200_bb0405","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","article-title":"A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I\/IIa clinical trial","volume":"26","author":"Kloor","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103200_bb0410","series-title":"Preventive dendritic cell vaccination induced TGF-\u03b2RII frameshift neoantigen-specific T-cells are linked to long-term disease-free survival in Lynch syndrome patients","author":"De Vries","year":"2025"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0415","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b\/2 trial","volume":"32","author":"D\u2019Alise","year":"2026","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103200_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003019","article-title":"Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors","volume":"9","author":"Vonderheide","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9_Supplement","key":"10.1016\/j.ctrv.2026.103200_bb0425","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-17-12","article-title":"Abstract PO2-17-12: phase I trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC","volume":"84","author":"Johnson","year":"2024","journal-title":"Cancer Res"},{"issue":"7_Supplement","key":"10.1016\/j.ctrv.2026.103200_bb0430","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT022","article-title":"Abstract CT022: mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: preliminary analysis from a phase I study","volume":"84","author":"Haldar","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0435","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/AOG.0000000000006113","article-title":"Effect of prior 9-valent human papillomavirus vaccination on subsequent lower genital tract dysplasia after cervical excisional surgery","volume":"147","author":"Joura","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0440","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/QAD.0000000000002928","article-title":"HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM","volume":"35","author":"Gosens","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2026.103200_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znad377","article-title":"Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients","volume":"111","author":"Wang","year":"2024","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103200_bb0450","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41576-020-0224-1","article-title":"Electronic health records and polygenic risk scores for predicting disease risk","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103200_bb0455","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103200_bb0460","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41571-020-0388-9","article-title":"Personalized early detection and prevention of breast cancer: ENVISION consensus statement","volume":"17","author":"Pashayan","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103200_bb0465","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.2025.24784","article-title":"Risk-based vs annual breast cancer screening: the WISDOM randomized clinical trial","volume":"335","author":"Esserman","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0470","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminoncol.2015.09.008","article-title":"The National Cancer Institute\u2019s PREVENT Cancer preclinical drug development program: overview, current projects, animal models, agent development strategies, and molecular targets","volume":"43","author":"Shoemaker","year":"2016","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0475","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2502760","article-title":"Structured exercise after adjuvant chemotherapy for Colon cancer","volume":"393","author":"Courneya","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103200_bb0480","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41579-018-0129-6","article-title":"Fusobacterium nucleatum - symbiont, opportunist and oncobacterium","volume":"17","author":"Brennan","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103200_bb0485","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103200_bb0490","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41585-020-0286-z","article-title":"The microbiome and gynaecological cancer development, prevention and therapy","volume":"17","author":"\u0141aniewski","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103200_bb0495","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12885-026-15655-6","article-title":"Modulating the gut microbiome to enhance cancer immunotherapy: a systematic review and meta-analysis of probiotics and FMT as adjuncts","volume":"26","author":"Hu","year":"2026","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103200_bb0500","doi-asserted-by":"crossref","DOI":"10.1097\/CEJ.0000000000001011","article-title":"Screening and prevention of second primary cancers by hospital-based oncology professionals","author":"Ben Ahmed","year":"2026","journal-title":"Eur J Cancer Prev"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:29:54Z","timestamp":1788733794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"alternative-id":["S0305737226001143"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103200","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103200"}}